Characteristics of patients, donors, and grafts
| Patients . | N (%) . |
|---|---|
| Median age (range) at HSCT, y | 6.9 (0.9-22.3) |
| Disease | |
| Acute leukemias (ALL and AML) | 10 (19.6) |
| Solid tumors (neuroblastoma, Ewing sarcoma, and rhabdomyosarcoma) | 34 (66.7) |
| Nonmalignant (immune deficiencies, EBV-associated LPD, sickle cell disease, and SAA) | 7 (13.7) |
| Donors, donor type: parental donor (mother/father) | 51 (100) |
| Conditioning regimens | |
| Melphalan + fludarabin + thiotepa | 50 (98) |
| Treosulfan + fludarabin | 1 (2) |
| ATLG dose | |
| 15 mg/kg | 8 (15.7) |
| 30 mg/kg | 34 (66.7) |
| 60 mg/kg | 9 (17.6) |
| Graft compositions, median (range) | |
| CD34+ cells × 10e6/kg | 15.12 (5.97-50.7) |
| CD3+ cells × 10e6/kg | 0.0257 (0.0056-0.1) |
| CD56+ cells × 10e6/kg | 62.17 (17.47-148.94) |
| CD19+ cells × 10e6/kg | 0.0156 (0.0015-0.1934) |
| Patients . | N (%) . |
|---|---|
| Median age (range) at HSCT, y | 6.9 (0.9-22.3) |
| Disease | |
| Acute leukemias (ALL and AML) | 10 (19.6) |
| Solid tumors (neuroblastoma, Ewing sarcoma, and rhabdomyosarcoma) | 34 (66.7) |
| Nonmalignant (immune deficiencies, EBV-associated LPD, sickle cell disease, and SAA) | 7 (13.7) |
| Donors, donor type: parental donor (mother/father) | 51 (100) |
| Conditioning regimens | |
| Melphalan + fludarabin + thiotepa | 50 (98) |
| Treosulfan + fludarabin | 1 (2) |
| ATLG dose | |
| 15 mg/kg | 8 (15.7) |
| 30 mg/kg | 34 (66.7) |
| 60 mg/kg | 9 (17.6) |
| Graft compositions, median (range) | |
| CD34+ cells × 10e6/kg | 15.12 (5.97-50.7) |
| CD3+ cells × 10e6/kg | 0.0257 (0.0056-0.1) |
| CD56+ cells × 10e6/kg | 62.17 (17.47-148.94) |
| CD19+ cells × 10e6/kg | 0.0156 (0.0015-0.1934) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; EBV, Epstein-Barr virus; LPD, lymphoproliferative disease; SAA, severe aplastic anemia.